

Government of India
Ministry of Chemicals & Fertilizers
Department of Pharmaceuticals
National Pharmaceutical Pricing Authority

5th / 3rd Floor,
1, Jai Singh Road,
Dated : 30.10.2012

Subject: Permission of nonClonable ID Nanotag on the medicinal packs under DPCO, 1995.

The subject relating to the usage and application of "nanotag technology" on the medical packs under DPCO, 1995 and inclusion of the cost for price fixation based on the norms notified by NPPA vide S.O. 2779(E) dated 14th December, 2011 was discussed in the 126th meeting of the Authority held on 13.09.2012.

2. Authority considered various issues involved in the use of nanotag technology on the medical packs such as the availability of infrastructure at various levels of the chain for capturing the data from the manufacturers to the pharmacists/consumers, the low coverage of medical packs under DPCO, 1995 (i.e. less than 20%), the additional costs involved in the use of nonClonable ID Nanotag particularly in respect of low cost medicines, the availability of various alternative technologies, reasonableness of the cost etc. The Authority also noted that primarily and essentially the use of this technology is a quality issue to check upon the spurious branded medicines and ultimately to benefit the manufacturers.

3. Keeping in view various aspects as indicated above therefore the Authority took a considered view that the subject matter requires a complete review and thus decided to dispense with the norms notified vide S.O. 2779(E) dated 14th December, 2011 and not to consider the same for price fixation/revision of prices of scheduled formulations under DPCO, 1995.



Director (Formulation)

By Fax/Speed Post

F. No. 10(M-7)/2012/Div I/NPPA
Government of India
Ministry of Chemicals & Fertilizers
Department of Pharmaceuticals
National Pharmaceutical Pricing Authority

5th / 3rd Floor,
1, Jai Singh Road,
YMCA Cultural Centre Building,
New Delhi – 110 001
Dated: 30.10.2012

To,

The Managing Director / C.E.O
M/s. Bilcare Ltd.,
601, ICC Trade Tower,
Pune - 411016
Fax: 020-30257701

Subject: Permission of nonClonable ID Nanotag on the medicinal packs under DPCO, 1995 – withdrawn regarding.

Sir,

I am directed to inform you that the subject relating to the use of nanotag technology on the medical packs under DPCO, 1995 and inclusion of the cost for price fixation based on the norms notified by NPPA vide S.O. 2779(E) dated 14th December, 2011 was discussed in the 126th meeting of the Authority held on 13.09.2012.

2. Authority considered various issues involved in the usage and application of "nanotag technology" on the medical packs such as the availability of infrastructure at various levels of the chain for capturing the data from the manufacturers to the pharmacists/consumers, the coverage of medical packs under DPCO, 1995 (i.e. less than 20%), the additional costs involved in the use of nonClonable ID Nanotag particularly in respect of low cost medicines, the availability of various alternative technologies, reasonableness of the cost etc. The Authority also noted that primarily and essentially the use of this technology is a quality issue to check upon the spurious branded medicines and ultimately to benefit the manufacturers.

3. Keeping in view various aspects as indicated above, the Authority therefore took a considered view that the subject matter requires a complete review and thus

decided to dispense with the norms notified vide S.O. 2779(E) dated 14th December, 2011 and not to consider the same for price fixation/revision of prices of scheduled formulations under DPCO, 1995.

4. In view of the above, the applications submitted by the manufacturers for the revision of prices on account of use of non-colanable ID nanotag have been closed. Consequently they are required to follow the existing ceiling pricing in this regard.

New Delhi - 110 001
Dated: 30.10.2012

To,

The Managing Director, C.B.O.
M/s. Biscoe Ltd.
501, ICD Trade Tower,
Pune - 411018
Fax: 020-30207701

Yours faithfully,

Deputy Director (Formulation)

Subject: Permission of non-colanable ID Nanotag on the scheduled packs under DPCO, 1995 - withdrawn regarding.

Sr.

I am directed to inform you that the subject relating to the use of nanotag technology on the medical packs under DPCO, 1995 and inclusion of the cost for price fixation based on the norms notified by NPPA vide S.O. 2779(E) dated 14th December, 2011 was discussed in the 126th meeting of the Authority held on 13.09.2012.

2. Authority considered various issues involved in the usage and application of nanotag technology on the medical packs with an awareness of infrastructure at various levels of the chain (i.e. capturing the data from the manufacturers to the pharmacovigilance), the coverage of medical packs under DPCO, 1995 (i.e. total less than 20%), the additional cost involved in the use of non-colanable ID Nanotag technology in respect of low cost medicines, the availability of various alternative technologies, responsibility of the owners. The Authority also noted that primarily and essentially the use of this technology is a quality issue to check upon the approved standard medicines and ultimately to benefit the manufacturers.

3. Keeping in view various aspects as indicated above, the Authority therefore decided to dispense with the norms notified vide S.O. 2779(E) dated 14th December, 2011 and not to consider the same for price fixation/revision of prices of scheduled formulations under DPCO, 1995.